KR20210105939A - 혈전성 또는 혈전색전성 장애 및/또는 혈전성 또는 혈전색전성 합병증의 치료 및/또는 예방을 위한 치환된 옥소피리딘 유도체 - Google Patents

혈전성 또는 혈전색전성 장애 및/또는 혈전성 또는 혈전색전성 합병증의 치료 및/또는 예방을 위한 치환된 옥소피리딘 유도체 Download PDF

Info

Publication number
KR20210105939A
KR20210105939A KR1020217022511A KR20217022511A KR20210105939A KR 20210105939 A KR20210105939 A KR 20210105939A KR 1020217022511 A KR1020217022511 A KR 1020217022511A KR 20217022511 A KR20217022511 A KR 20217022511A KR 20210105939 A KR20210105939 A KR 20210105939A
Authority
KR
South Korea
Prior art keywords
stroke
disorders
solvate
salt
arteries
Prior art date
Application number
KR1020217022511A
Other languages
English (en)
Korean (ko)
Inventor
슈테판 하이트마이어
하르디 문들
Original Assignee
바이엘 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 악티엔게젤샤프트 filed Critical 바이엘 악티엔게젤샤프트
Publication of KR20210105939A publication Critical patent/KR20210105939A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217022511A 2018-12-17 2019-12-10 혈전성 또는 혈전색전성 장애 및/또는 혈전성 또는 혈전색전성 합병증의 치료 및/또는 예방을 위한 치환된 옥소피리딘 유도체 KR20210105939A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18213216.7 2018-12-17
EP18213216 2018-12-17
PCT/EP2019/084449 WO2020126682A1 (en) 2018-12-17 2019-12-10 Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications

Publications (1)

Publication Number Publication Date
KR20210105939A true KR20210105939A (ko) 2021-08-27

Family

ID=64744522

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217022511A KR20210105939A (ko) 2018-12-17 2019-12-10 혈전성 또는 혈전색전성 장애 및/또는 혈전성 또는 혈전색전성 합병증의 치료 및/또는 예방을 위한 치환된 옥소피리딘 유도체

Country Status (7)

Country Link
US (1) US20220306602A1 (zh)
EP (1) EP3898611A1 (zh)
JP (1) JP2022513919A (zh)
KR (1) KR20210105939A (zh)
CN (1) CN113166099A (zh)
CA (1) CA3123324A1 (zh)
WO (1) WO2020126682A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006710RA (en) * 2018-03-15 2020-08-28 Bayer Ag Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives
MX2023010614A (es) * 2021-03-09 2023-09-19 Bayer Ag Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途
CN116947818B (zh) * 2023-09-18 2023-12-19 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3138839B1 (en) * 2014-02-14 2020-10-28 Sichuan Haisco Pharmaceutical Co., Ltd. Pyridone or pyrimidone derivative, preparation method therefor and application thereof
WO2016205482A1 (en) * 2015-06-19 2016-12-22 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
EP3331872B1 (en) * 2015-08-05 2019-09-25 Bristol-Myers Squibb Company Novel substituted glycine derived fxia inhibitors
UA125520C2 (uk) * 2016-08-31 2022-04-13 Джянгсу Хенгруй Медісін Ко., Лтд. Похідні оксопіколінаміду, спосіб їх отримання та їх фармацевтичне застосування

Also Published As

Publication number Publication date
CN113166099A (zh) 2021-07-23
WO2020126682A1 (en) 2020-06-25
US20220306602A1 (en) 2022-09-29
JP2022513919A (ja) 2022-02-09
CA3123324A1 (en) 2020-06-25
EP3898611A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
KR20210105939A (ko) 혈전성 또는 혈전색전성 장애 및/또는 혈전성 또는 혈전색전성 합병증의 치료 및/또는 예방을 위한 치환된 옥소피리딘 유도체
JP6368367B2 (ja) 置換オキソピリジン誘導体
ES2409090T3 (es) Formulaciones de dosis unitaria y métodos para el tratamiento de trombosis con un inhibidor oral del factor Xa
JP5116681B2 (ja) ２−アミノエトキシ酢酸誘導体およびそれらの使用
CZ303715B6 (cs) Farmaceutická kombinace 5-chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiofenkarboxamidu, léciva tuto kombinaci obsahující a její pouzití
CN105555767A (zh) 取代的氧代吡啶衍生物及其作为因子xia/血浆的用途
MX2007009100A (es) Prevencion y tratamiento de trastornos tromboembolicos.
CN106687458B (zh) 取代的氧代吡啶衍生物
KR20070110395A (ko) 혈전증 병상을 치료하고 예방하기 위한 디오스메틴 유도체
JP2018509426A (ja) 血栓症の治療のための因子ＸＩａ阻害剤としてのオキソピリジン誘導体
US20180346424A1 (en) Substituted oxopyridine derivatives
US10077265B2 (en) Substituted oxopyridine derivatives
JP2009538846A5 (zh)
US20110003804A1 (en) Oxazolidinones For the Treatment and/or Prophylaxis of Heart Failure
JP2008506745A (ja) Ｘａ因子活性を阻害する新規化合物
JP2021521132A (ja) 置換オキソピリジン誘導体
CN113116885A (zh) 一种茶多酚类化合物在制备抗血栓药物中的应用
EP2138178A1 (en) Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
JP2004503509A (ja) メラガトラン及びＶＩＩａ因子阻害剤を含んでなる組合せ製品
RU2792645C2 (ru) Замещенное оксопиридиновое производное
JP2005525336A (ja) 血栓性および炎症性障害の治療のためのナトリウム／水素交換体の阻害剤の使用
KR20100015675A (ko) 폐 고혈압의 치료 및 예방을 위한 옥사졸리디논
HUT77739A (hu) Orálisan adagolható, dihidro-imidazol-származékot tartalmazó trombolitikus szer